I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AASLD 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche
A Comparative Analysis Of Elecsys GALAD And Elecsys GAAD Scores To Detect Early-Stage Hepatocellular Carcinoma In An International Cohort
This study compared the clinical performance of the Elecsys GALAD (gender [sex], age, alpha-fetoprotein [AFP] Lens culinaris agglutinin-reactive fraction of AFP [AFP-L3] and protein-induced by vitamin K absence-II [PIVKA-II]) and Elecsys GAAD (gender [sex], age, AFP and PIVKA-II) algorithms in differentiating hepatocellular carcinoma and benign chronic liver disease.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche and Genentech
Clinicopathological characteristics and outcome of hepatocellular carcinoma patients who achieved durable partial response or stable disease status in IMbrave150 study
IMbrave150 study, a phase III randomized control trial, showed statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) with atezolizumab-bevacizumab (atezo-bev) over sorafenib in patients with advanced hepatocellular carcinoma (HCC) who have never received any prior systemic therapies. Patients who achieved complete response (CR), durable partial response (PR) and durable stable disease (SD) in the atezo-bev group (intent-to-treat population) of IMbrave150 study were analysed.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche and Genentech
Predicting treatment choices for unresectable hepatocellular carcinoma (HCC): Results from a patient preference study
This study quantified patients’ benefit-risk preferences for attributes associated with firstline systemic therapies approved in the United States for the treatment of unresectable HCC. The study also assessed patients’ preferences for different hypothetical medication profiles defined by varying levels of treatment benefits and risks.